Rabbit NCAM1 Antibody
| Catalog number: | B2013004 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 50 uL |
| Molecular Weight or Concentration: | N/A |
| Supplied as: | Solution |
| Applications: | molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | NCAM1 antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Huang H, Liu Y, Ouyang X, Wang H, Zhang Y. Identification of a peptide targeting CD56 Immunobiology. 2020 Jul;225(4):151982.
- Buzhor E, Omer D, Harari-Steinberg O, Dotan Z, Vax E, Pri-Chen S, Metsuyanim S, Pleniceanu O, Goldstein RS, Dekel B. Reactivation of NCAM1 defines a subpopulation of human adult kidney epithelial cells with clonogenic and stem/progenitor properties Am J Pathol. 2013 Nov;183(5):1621-1633.
- Ghaderi F, Ahmadvand S, Ramezani A, Montazer M, Ghaderi A. Production and characterization of monoclonal antibody against a triple negative breast cancer cell line Biochem Biophys Res Commun. 2018 Oct 20;505(1):181-186.
- Mlika M, Zendah I, Braham E, El Mezni F. CD56 antibody: old-fashioned or still trendy in endocrine lung tumors J Immunoassay Immunochem. 2015;36(4):414-9.
- Mikulak J, Oriolo F, Zaghi E, Di Vito C, Mavilio D. Natural killer cells in HIV-1 infection and therapy AIDS. 2017 Nov 13;31(17):2317-2330.
- Wagner AK, Alici E, Lowdell MW. Characterization of human natural killer cells for therapeutic use Cytotherapy. 2019 Mar;21(3):315-326.
- Yap LW, Brok J, Pritchard-Jones K. Role of CD56 in Normal Kidney Development and Wilms Tumorigenesis Fetal Pediatr Pathol. 2017 Feb;36(1):62-75.
- Tur MK, Etschmann B, Benz A, Leich E, Waller C, Schuh K, Rosenwald A, Ertl G, Kienitz A, Haaf AT, Bruninger A, Gattenlhner S. The 140-kD isoform of CD56 (NCAM1) directs the molecular pathogenesis of ischemic cardiomyopathy Am J Pathol. 2013 Apr;182(4):1205-18.
- Aldabagh B, Joo J, Yu SS. Merkel cell carcinoma: current status of targeted and future potential for immunotherapies Semin Cutan Med Surg. 2014 Jun;33(2):76-82.
